154327-27-2

Basic information

• Product Name: 2-CHLORO-5-FLUOROBENZOTHIAZOLE
• Synonyms: 2-CHLORO-5-FLUOROBENZOTHIAZOLE;2-Chloro-5-fluorobenzo[d]thiazole
• CAS NO: 154327-27-2
• Molecular Formula: C₇H₃ClFNS
• Molecular Weight: 187.62
• Mol File: 154327-27-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 253.0±13.0 °C(Predicted)
• Appearance: /
• Density: 1.532±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.36±0.10(Predicted)
• CAS DataBase Reference: 2-CHLORO-5-FLUOROBENZOTHIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5-FLUOROBENZOTHIAZOLE(154327-27-2)
• EPA Substance Registry System: 2-CHLORO-5-FLUOROBENZOTHIAZOLE(154327-27-2)

Safety Data

• Hazardous Substances Data: 154327-27-2(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

Upstream product

• 155559-81-2 5-fluoro-2-mercaptobenzothiazole 
• 20358-07-0 2-amino-5-fluorobenzothiazole 
• 367-30-6 2,5-difluoroaniline 
• 372-19-0 meta-fluoroaniline 

Downstream Products

• 1146693-14-2 [4-(6-fluoro-benzothiazol-2-yloxy)-phenyl]-methanol 

Relevant articles and documents

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Preparation, antibacterial evaluation and preliminary structure-activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives

In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics.